Beijing-based Sinovation (Beijing) Medical Technology Co., Ltd., a leader in neurosurgery diagnosis, minimally invasive procedure treatment, and smart industry platform, has reportedly raised over RMB 100 million (USD 14 million) in a Series D+ financing round. The round saw participation from notable investors such as Xinda Kunpeng Investment, Tsing Ventures, PEAKVEST, Spring Oasis Investments, and DNV Capital.
Milestone Achievements in Neurosurgery Technology
Sinovation boasts a portfolio of innovative medical technologies, including magnetic resonance-guided laser interstitial thermotherapy (LITT), which was approved for marketing in China in April 2023. This technology is recognized as the world’s first magnetic resonance monitoring laser ablation treatment system targeting the brain, developed by a Chinese company. Further solidifying its position in the global market, Sinovation’s in-house developed 3D Structured light registered surgical robot received approval in the US in June 2023, marking it as the world’s first of its kind.
Regulatory Approvals and Intellectual Property Strength
In addition to these breakthroughs, the company has an impressive regulatory and intellectual property portfolio. Sinovation has 4 products with fast-track status and 7 products with Category III approvals, demonstrating its commitment to innovation and quality in medical technology. The company also holds over 90 patents, a testament to its dedication to research and development in the field of neurosurgery and minimally invasive procedures.-Fineline Info & Tech
